The Developmental Research Program (DRP) will provide seed funding to meritorious translational projects that have the potential for significantly advancing our ability to prevent, detect, diagnose, stage, or treat multiple myeloma. Project proposals will be selected in a rigorous, peer-reviewed, two-tiered process, starting with a once-yeariy request for applications that will be communicated to investigators at all three participafing institutions. In this first round, proposals will be limited to four pages, and required to assume the format of an NIH R01 applicafion, incorporafing specific aims, background and significance, preliminary studies, and research design and methods. These proposals will be reviewed by the DRP Director and Co- Director to identify those that meet the pre-specified eligibility criteria, and these will be invited to submit a full, ten-page applicafion, using the same format with the inclusion of a budget and justification. During this second fier, proposals will be reviewed by the DRP Review Committee, which will include Leaders and/or Co-Leaders of each of the SPORE Projects, Directors and/or Co-Directors of SPORE Cores, and at least four members of the External Scientific Advisory Board, and four members of the Internal Scientific Advisory Board. Up to four projects each year will be selected for funding and supported for one year, during which progress reports will be monitored every six months. Renewal of support may be possible for a second year, but will require the project to successfully compete with the next year's pool of proposals. Through this mechanism, the specific aims of the DRP are: 1. To support novel, highly translational research projects that take maximum advantage of the new research opportunities afforded by the SPORE;2. To build and foster new collaborafions among scientists within SPOREs, or with scienfists outside the SPORE mechanism;and 3. To provide.scientific flexibility to the SPORE that will allow promofion of promising DRP projects to full Project status. Prior to the submission of this applicafion, the standard operating procedure outlined above was successfully tested, and led to the selection of several promising proposals to serve as examples of the types of projects that would be considered for support. Notably, these come from a diverse group of invesfigators interested in a variety of approaches with important translational implicafions, and support the future strength of the DRP.
The DRP will be a source of seed funding to support innovative, highly translafional approaches with a great potential for advancing our future ability to prevent, detect, diagnose, stage, or treat multiple myeloma.
|Zhang, Jun; Medeiros, L Jeffrey; Young, Ken H (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 8:351|
|Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420|
|Zhou, Liang; Zhang, Yu; Sampath, Deepak et al. (2018) Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118:388-397|
|Davenport, Clemontina A; Maity, Arnab; Baladandayuthapani, Veerabhadran (2018) Functional interaction-based nonlinear models with application to multiplatform genomics data. Stat Med 37:2715-2733|
|Yao, Z; Deng, L; Xu-Monette, Z Y et al. (2018) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:353-363|
|Zhang, Xiaohui; Lee, Hans C; Shirazi, Fazal et al. (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:2224-2239|
|Thomas, Sheeba K; Cha, Soung-Chul; Smith, D Lynne et al. (2018) Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18:187|
|Xu-Monette, Zijun Y; Zhou, Jianfeng; Young, Ken H (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68-83|
|Purushothaman, Anurag; Bandari, Shyam K; Chandrashekar, Darshan S et al. (2017) Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget 8:73723-73732|
|Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357|
Showing the most recent 10 out of 203 publications